RxDoctor Payments DataLook up a doctor →

Fred Odago, MD

Neurology · Lexington, KYNPI 1356872238

Payments from drug & device makers

$28,428in general payments, 2019–2025

Across 490 payments — averaging $58.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eisai Inc.$15K
  • Genentech USA, Inc.$4K
  • AbbVie$3K
  • EMD Serono, Inc.$2K
  • Novartis$862
  • Pfizer$746
  • plus $4K from 29 others

What the payments were for

  • Consulting fees$12,58544%
  • Speaking & faculty fees$4,51516%
  • Travel & lodging$1,5986%
  • Food & beverage$9,50233%
  • Education$2281%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$28,428 in reported general payments places this provider in the 80th percentile of 210 neurology providers in Kentucky.

See all neurology providers in Kentucky

Medicare billing

Part B allowed, 2024
$77,462
Medicare patients
243
Services billed
2,997

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CopaxoneGlatiramer Acetate50$279,218
Kesimpta PenOfatumumab16$136,636
AptiomEslicarbazepine Acetate19$39,835
Nurtec OdtRimegepant Sulfate23$36,014
UbrelvyUbrogepant26$31,221
XcopriCenobamate15$29,867
Aimovig AutoinjectorErenumab-Aooe29$22,794
Emgality PenGalcanezumab-Gnlm27$22,116
QuliptaAtogepant20$21,483
RytaryCarbidopa/Levodopa24$14,570
Dalfampridine ErDalfampridine31$12,548
Topiramate ErTopiramate14$6,394
Pregabalin57$5,912
Rivastigmine18$4,603
Gabapentin286$3,107

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Copaxone$29$279,21850 claims
AbbVieUbrelvy, Qulipta$2,626$52,70446 claims
PfizerNurtec Odt$746$36,01423 claims
SK Life Science, Inc.Xcopri$353$29,86715 claims
Amneal Pharmaceuticals LLCRytary$27$14,57024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 210 neurology providers in Kentucky.

Other neurology in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →